Clinician-assessed depression and HAART adherence in HIV-infected individuals in methadone maintenance treatment

Jeffrey S. Gonzalez, Christina Psaros, Abigail Batchelder, Allison Applebaum, Howard Newville, Steven Safren

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background: The impact of measurement methods on the relationship between depression and HIV treatment adherence has not been adequately examined. Purpose: The purpose of this paper is to examine the relationship between clinician- and patient-rated depression and HIV medication adherence. Methods: The participants were 91 HIV-infected individuals in methadone maintenance. Depression was assessed via clinician ratings (Clinical Global Impression Scale and Montgomery Asberg Depression Rating Scale) and self-report (Beck Depression Inventory-Short Form). Clinicians rated substance abuse using the Clinical Global Impression Scale and a structured interview. HIV medication adherence was measured over the following 2 weeks using electronic caps. Results: Each unit increase in the Clinical Global Impression Scale was associated with 75% increased odds of nonadherence (OR=1.75, p=0.002, 95% CI=1.23-2.48). Similarly, for each standard deviation Montgomery Asberg Depression Rating Scale increase, there was a 2.6-fold increased odds of nonadherence (OR=2.60, p=0.001, 95% CI=1.45-4.67). Substance abuse and self-reported depression severity were not significantly related to adherence. Conclusions: Clinician-rated depression severity was a strong predictor of nonadherence. Assessment methods may influence the relationship between depression and HIV nonadherence.

Original languageEnglish (US)
Pages (from-to)120-126
Number of pages7
JournalAnnals of Behavioral Medicine
Volume42
Issue number1
DOIs
StatePublished - Aug 2011
Externally publishedYes

Fingerprint

Methadone
Highly Active Antiretroviral Therapy
HIV
Depression
Therapeutics
Medication Adherence
Substance-Related Disorders
Self Report
Interviews
Equipment and Supplies

Keywords

  • Adherence
  • Assessment
  • Depression
  • HAART
  • HIV
  • Methadone maintenance

ASJC Scopus subject areas

  • Psychology(all)
  • Psychiatry and Mental health
  • Medicine(all)

Cite this

Clinician-assessed depression and HAART adherence in HIV-infected individuals in methadone maintenance treatment. / Gonzalez, Jeffrey S.; Psaros, Christina; Batchelder, Abigail; Applebaum, Allison; Newville, Howard; Safren, Steven.

In: Annals of Behavioral Medicine, Vol. 42, No. 1, 08.2011, p. 120-126.

Research output: Contribution to journalArticle

Gonzalez, Jeffrey S. ; Psaros, Christina ; Batchelder, Abigail ; Applebaum, Allison ; Newville, Howard ; Safren, Steven. / Clinician-assessed depression and HAART adherence in HIV-infected individuals in methadone maintenance treatment. In: Annals of Behavioral Medicine. 2011 ; Vol. 42, No. 1. pp. 120-126.
@article{5b2c7123eef447219ac3027cabf03142,
title = "Clinician-assessed depression and HAART adherence in HIV-infected individuals in methadone maintenance treatment",
abstract = "Background: The impact of measurement methods on the relationship between depression and HIV treatment adherence has not been adequately examined. Purpose: The purpose of this paper is to examine the relationship between clinician- and patient-rated depression and HIV medication adherence. Methods: The participants were 91 HIV-infected individuals in methadone maintenance. Depression was assessed via clinician ratings (Clinical Global Impression Scale and Montgomery Asberg Depression Rating Scale) and self-report (Beck Depression Inventory-Short Form). Clinicians rated substance abuse using the Clinical Global Impression Scale and a structured interview. HIV medication adherence was measured over the following 2 weeks using electronic caps. Results: Each unit increase in the Clinical Global Impression Scale was associated with 75{\%} increased odds of nonadherence (OR=1.75, p=0.002, 95{\%} CI=1.23-2.48). Similarly, for each standard deviation Montgomery Asberg Depression Rating Scale increase, there was a 2.6-fold increased odds of nonadherence (OR=2.60, p=0.001, 95{\%} CI=1.45-4.67). Substance abuse and self-reported depression severity were not significantly related to adherence. Conclusions: Clinician-rated depression severity was a strong predictor of nonadherence. Assessment methods may influence the relationship between depression and HIV nonadherence.",
keywords = "Adherence, Assessment, Depression, HAART, HIV, Methadone maintenance",
author = "Gonzalez, {Jeffrey S.} and Christina Psaros and Abigail Batchelder and Allison Applebaum and Howard Newville and Steven Safren",
year = "2011",
month = "8",
doi = "10.1007/s12160-011-9268-y",
language = "English (US)",
volume = "42",
pages = "120--126",
journal = "Annals of Behavioral Medicine",
issn = "0883-6612",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Clinician-assessed depression and HAART adherence in HIV-infected individuals in methadone maintenance treatment

AU - Gonzalez, Jeffrey S.

AU - Psaros, Christina

AU - Batchelder, Abigail

AU - Applebaum, Allison

AU - Newville, Howard

AU - Safren, Steven

PY - 2011/8

Y1 - 2011/8

N2 - Background: The impact of measurement methods on the relationship between depression and HIV treatment adherence has not been adequately examined. Purpose: The purpose of this paper is to examine the relationship between clinician- and patient-rated depression and HIV medication adherence. Methods: The participants were 91 HIV-infected individuals in methadone maintenance. Depression was assessed via clinician ratings (Clinical Global Impression Scale and Montgomery Asberg Depression Rating Scale) and self-report (Beck Depression Inventory-Short Form). Clinicians rated substance abuse using the Clinical Global Impression Scale and a structured interview. HIV medication adherence was measured over the following 2 weeks using electronic caps. Results: Each unit increase in the Clinical Global Impression Scale was associated with 75% increased odds of nonadherence (OR=1.75, p=0.002, 95% CI=1.23-2.48). Similarly, for each standard deviation Montgomery Asberg Depression Rating Scale increase, there was a 2.6-fold increased odds of nonadherence (OR=2.60, p=0.001, 95% CI=1.45-4.67). Substance abuse and self-reported depression severity were not significantly related to adherence. Conclusions: Clinician-rated depression severity was a strong predictor of nonadherence. Assessment methods may influence the relationship between depression and HIV nonadherence.

AB - Background: The impact of measurement methods on the relationship between depression and HIV treatment adherence has not been adequately examined. Purpose: The purpose of this paper is to examine the relationship between clinician- and patient-rated depression and HIV medication adherence. Methods: The participants were 91 HIV-infected individuals in methadone maintenance. Depression was assessed via clinician ratings (Clinical Global Impression Scale and Montgomery Asberg Depression Rating Scale) and self-report (Beck Depression Inventory-Short Form). Clinicians rated substance abuse using the Clinical Global Impression Scale and a structured interview. HIV medication adherence was measured over the following 2 weeks using electronic caps. Results: Each unit increase in the Clinical Global Impression Scale was associated with 75% increased odds of nonadherence (OR=1.75, p=0.002, 95% CI=1.23-2.48). Similarly, for each standard deviation Montgomery Asberg Depression Rating Scale increase, there was a 2.6-fold increased odds of nonadherence (OR=2.60, p=0.001, 95% CI=1.45-4.67). Substance abuse and self-reported depression severity were not significantly related to adherence. Conclusions: Clinician-rated depression severity was a strong predictor of nonadherence. Assessment methods may influence the relationship between depression and HIV nonadherence.

KW - Adherence

KW - Assessment

KW - Depression

KW - HAART

KW - HIV

KW - Methadone maintenance

UR - http://www.scopus.com/inward/record.url?scp=79960584325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960584325&partnerID=8YFLogxK

U2 - 10.1007/s12160-011-9268-y

DO - 10.1007/s12160-011-9268-y

M3 - Article

C2 - 21503833

AN - SCOPUS:79960584325

VL - 42

SP - 120

EP - 126

JO - Annals of Behavioral Medicine

JF - Annals of Behavioral Medicine

SN - 0883-6612

IS - 1

ER -